In spring 2017, the American Diabetes Association tasked a working group with examining soaring insulin list prices,1 which had nearly tripled between 2002 and 2013.2 Because pharmaceutical spending represents a prime contributor to the escalating costs of diabetes care in the United States,2,3 these increases in insulin pricing warranted analysis.
Crowley MJ, Maciejewski ML. Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? JAMA. 2018;320(1):38–39. doi:10.1001/jama.2018.8033
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: